Adolescent Asthma
Conditions
Brief summary
Studies to evaluate the safety, tolerability, pharmacodynamics, and efficacy of RSS0343 tablets in patients with non-cystic fibrosis bronchiectasis
Interventions
DRUGRSS0343 Tabella
RSS0343 tablets, oral;
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age 18-75 years old (including boundary values), male and female. 2. Female subjects weigh ≥45 kg and male subjects weigh ≥50 kg. 3. HRCT shows bronchiectasis affecting one or more lobes of the lung and is confirmed by the clinician as NCFB. 4. The expected survival is greater than 12 months. 5. Informed consent was signed before the trial. 6. Potentially fertile subjects voluntarily take appropriate contraceptive measures.
Exclusion criteria
1. Patients with pulmonary hypertension or chronic obstructive pulmonary disease (COPD) or asthma as determined by the investigators were the primary diagnosis were screened. 2. An active, symptomatic infection caused by respiratory viruses, including COVID-19, influenza viruses, etc. 3. Have psoriasis or lichen planus. 4. Have Wright's disease/keratosis or hemorrhagic keratosis, or reactive arthritis. 5. Have chlorine acne, large common warts, or keratodermatitis. 6. Has diabetic foot. 7. Have periodontal disease, oral infection, or loose teeth. 8. History of malignant tumor within 5 years prior to screening. 9. Screening subjects with a history of liver disease or currently receiving treatment for liver disease, including but not limited to acute or chronic hepatitis, cirrhosis, or liver failure. 10. Researchers consider any other unstable clinical disease. 11. Oral or inhaled antibiotics were received 4 weeks prior to first administration. 12. Immunosuppressants were administered 4 weeks before the first dose. 13. Received drugs within 4 weeks prior to screening that may cause hyperkeratosis of the skin. 14. Received live attenuated vaccine within 30 days prior to initial administration. 15. Participated in clinical trials of any medical device within 3 months prior to screening. 16. Active hepatitis B virus infection, active hepatitis C virus infection, or known HIV infection or known syphilis infection. 17. Drug abusers. 18. Current smoker or former smoker for less than 3 months. 19. Suspected allergy to the investigational product or any component of the investigational product, or severe allergy to any drug, food, toxin or other exposure. 20. Pregnant or lactating women. 21. The subjects were unable to complete the questionnaires due to their limited educational level, or neither the subjects themselves nor their families could fill in the subject log card. 22. The researchers determined that there were other circumstances that were not suitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of occurrences of AEs | Day 1 to Day56 |
| the frequency of occurrence of AEs | Day 1 to Day56 |
Secondary
| Measure | Time frame |
|---|---|
| RSS0343 amount of tablets of their metabolites in the blood | Day7, Day14, Day21, Day 28 |
| Changes in the concentrations of active neutrophil elastase (NE) in sputum | Day7, Day14, Day21, Day 28, Day 56 |
| Changes in the concentrations of cathepsin G (CatG) in sputum | Day7, Day14, Day21, Day 28, Day 56 |
| Changes in the concentrations of enzyme protease 3 (PR3) in sputum | Day7, Day14, Day21, Day 28, Day 56 |
Countries
China
Contacts
Primary ContactZi Lin
Outcome results
None listed